Prosensa Holding NV
(NASDAQ : RNA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
0.87%84.340.9%$1036.24m
KITEKite Pharma, Inc.
0.17%179.6216.1%$788.52m
CELGCelgene Corporation
-0.55%144.151.1%$523.29m
AMGNAmgen Inc.
-0.13%186.051.1%$498.72m
BIIBBiogen Inc.
-0.28%316.621.2%$434.80m
REGNRegeneron Pharmaceuticals, Inc.
-0.42%436.322.7%$368.74m
ALNYAlnylam Pharmaceuticals, Inc
-3.88%112.4910.7%$259.79m
ALXNAlexion Pharmaceuticals, Inc.
-2.78%139.961.9%$231.82m
JUNOJuno Therapeutics, Inc.
-1.47%41.7114.6%$228.14m
INCYIncyte Corporation
-0.59%109.042.6%$223.72m
VRTXVertex Pharmaceuticals Incorporated
0.01%149.121.9%$216.35m
ILMNIllumina, Inc.
-1.07%199.233.5%$163.28m
BLUEBluebird Bio, Inc.
-1.84%128.1019.3%$146.63m
BMRNBioMarin Pharmaceutical Inc.
-1.36%93.114.4%$140.54m
CLVSClovis Oncology, Inc.
-3.58%73.2418.0%$132.64m

Company Profile

Prosensa Holding NV engages in the development of ribonucleic acid-modulating, or RNA-modulating, therapeutics for the treatment of genetic disorders. The company focuses on rare neuromuscular and neurodegenerative disorders, Duchenne muscular dystrophy, myotonic dystrophy and Huntington's disease. It has developed a portfolio of clinical and pre-clinical RNA-based drug candidates. Prosensa's current clinical portfolio is focused on the treatment of Duchenne Muscular Dystrophy. The company was founded in 2002 and is headquartered in Leiden, the Netherlands.